ROFERON A 9miu/0.5ml %v/v Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

roferon a 9miu/0.5ml %v/v solution for injection

roche products limited - interferon alfa-2a - solution for injection - 9miu/0.5ml %v/v - interferons

Roferon-A 9million units/0.5ml solution for injection pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roferon-a 9million units/0.5ml solution for injection pre-filled syringes

roche products ltd - interferon alfa-2a - solution for injection - 18mega unit/1ml

Roferon-A 6million units/0.5ml solution for injection pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roferon-a 6million units/0.5ml solution for injection pre-filled syringes

roche products ltd - interferon alfa-2a - solution for injection - 12mega unit/1ml

Roferon-A 3million units/0.5ml solution for injection pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roferon-a 3million units/0.5ml solution for injection pre-filled syringes

roche products ltd - interferon alfa-2a - solution for injection - 6mega unit/1ml

Roferon-A 4.5million units/0.5ml solution for injection pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roferon-a 4.5million units/0.5ml solution for injection pre-filled syringes

roche products ltd - interferon alfa-2a - solution for injection - 9mega unit/1ml

Roferon-A solution for s/c injection Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roferon-a solution for s/c injection

f. hoffmann-la roche ltd. - interferon alfa-2a - solution for s/c injection - 3000000iu/0,5ml

ROFERON - A 3 MIU/0.5 ML Israel - English - Ministry of Health

roferon - a 3 miu/0.5 ml

roche pharmaceuticals (israel) ltd - interferon alfa 2a 3 miu / 0.5 ml - solution for injection - interferon alfa-2a - condylumata acuminata. hepatitis b,c. hairy cell leukemia. cml. aids related kaposis sarcoma. renal cell carcinoma.follicular non-hodgkin's lymphoma. patients with ajcc stage ii malignant melanoma (breslow tumour thickness > 1.5 mm, no lymph node involvement or cutaneous spread) who are free of disease after surgery.

ROFERON - A 4.5 MIU/0.5 ML Israel - English - Ministry of Health

roferon - a 4.5 miu/0.5 ml

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ROFERON - A 6 MIU/0.5 ML Israel - English - Ministry of Health

roferon - a 6 miu/0.5 ml

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ROFERON - A 9 MIU/0.5 ML Israel - English - Ministry of Health

roferon - a 9 miu/0.5 ml

roche pharmaceuticals (israel) ltd - interferon alfa 2a 9 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m